STOCK TITAN

GROOVE BOTANICALS INC (GRVE) Financials

GRVE
Trailing 12 months to June 30, 2026
Revenue Not reported for the trailing 12 months
Net Income Not reported for the trailing 12 months
EPS (Diluted) -$0.01 0.0% YoY
Free Cash Flow Not reported for the trailing 12 months
Market Cap $253K as of Sep 15, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m no net income reported
Price / Book n/m negative shareholder equity, so no book multiple, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRVE SEC filings page.

This page shows GROOVE BOTANICALS INC (GRVE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GRVE FY2026

Balance-sheet deterioration is the dominant mechanic: obligations expanded while reported assets remained only a few thousand dollars.

From FY2023 to FY2026, liabilities increased from $443K to $1.5M while assets stayed near $4K, pushing equity further negative. That combination indicates a business financed by obligations rather than an operating asset base.

Liquidity is exceptionally constrained: the current ratio remained around 0.0x through FY2026, meaning reported current assets were negligible relative to current liabilities. Revenue, net income, and operating cash flow are not reported for the recent periods, so operating performance and cash conversion cannot be assessed from these figures.

Some figures from recent filings were inconsistent and were omitted from this summary.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

GROOVE BOTANICALS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)
$0.00
QoQ+100.0%

GROOVE BOTANICALS INC earned $0.00 per diluted share (EPS) in Q1 2027. Against the prior quarter it is up 100.0%.

Revenue

Not reported for Q1 2027.

EBITDA

Not reported for Q1 2027.

Net Income

Not reported for Q1 2027.

Cash & Balance Sheet

Cash & Debt
$1K
YoY-45.4%
QoQ-0.5%

GROOVE BOTANICALS INC held $1K in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding
60M
YoY0.0%
QoQ0.0%

GROOVE BOTANICALS INC had 60M shares outstanding in Q1 2027. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

None of these metrics is reported for Q1 2027.

Capital Allocation

None of these metrics is reported for Q1 2027.

GRVE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRVE quarterly income statement
MetricQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q
SG&A ExpensesN/AN/A$16K-7.0%$17K-9.9%N/AN/A$17K$18K
Operating IncomeN/AN/AN/A-$32K-8.5%N/AN/AN/A-$30K
Net IncomeN/AN/AN/A-$32K-8.5%N/AN/AN/A-$30K
EPS (Basic)N/AN/AN/AN/A$0.00-$0.010.0%$0.00$0.00
EPS (Diluted)$0.00-$0.010.0%$0.00$0.00$0.00-$0.010.0%$0.00$0.00
Diluted Shares (Avg)N/AN/AN/AN/A60M0.0%N/A60M+1.7%60M+1.7%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, Income Tax.

GRVE Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRVE quarterly balance sheet
MetricQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q
Total Assets$3K-31.5%$4K-1.9%$6K+32.3%$8K-26.6%$4K+20.7%$5K+111.0%$5K+88.9%$11K+245.2%
Current Assets$3K-31.5%$4K-1.9%$6K+32.3%$8K-26.6%$4K+20.7%$5K+111.0%$5K+88.9%$11K+245.2%
Cash & Equivalents$1K-45.4%$2K-26.4%$1K+19.4%$1K-75.7%$3K+3.8%$2K+21.0%$1K-41.8%$6K+115.5%
Short-Term Investments$0$0$0$0$0$0$0$0
Long-Term Investments$0$0$0$0$0$0$0$0
Total Liabilities$1.5M+28.2%$1.5M+32.2%$1.4M+34.6%$1.3M+37.0%$1.2M+41.1%$1.1M+46.1%$1.0M+58.5%$947K+50.7%
Current Liabilities$1.5M+28.2%$1.5M+32.2%$1.4M+34.6%$1.3M+37.0%$1.2M+41.1%$1.1M+46.1%$1.0M+57.8%$947K+47.5%
Non-Current Liabilities$0$0$0$0$0$0$0+100.0%$0+100.0%
Total Equity-$1.5M-28.4%-$1.5M-32.3%-$1.4M-34.6%-$1.3M-37.8%-$1.2M-41.2%-$1.1M-45.9%-$1.0M-58.4%-$936K-49.7%
Retained Earnings-$35.6M-1.0%-$35.6M-1.0%-$35.5M-1.0%-$35.4M-1.0%-$35.3M-1.0%-$35.2M-1.0%-$35.1M-1.3%-$35.0M-1.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

GRVE Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRVE quarterly cash flow statement
MetricQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q
Operating Cash FlowN/A-$16K+11.6%-$20K-$36K+16.0%N/A-$18KN/A-$43K
Investing Cash Flow$0N/AN/AN/A$0N/AN/AN/A
Financing Cash FlowN/A$16K-15.3%$20K-4.7%$35K-25.0%N/A$19K$21K+92.9%$46K

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

GRVE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRVE quarterly financial ratios
MetricQ1'2710-QQ4'2610-QQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q
Return on AssetsN/AN/AN/A-396.7%-128.5ppN/AN/AN/A-268.2%
Current Ratio0.000.0x0.000.0x0.000.0x0.010.0x0.000.0x0.000.0x0.000.0x0.010.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is GROOVE BOTANICALS INC's earnings per share (EPS)?

GROOVE BOTANICALS INC (GRVE) reported diluted earnings per share of -$0.01 for fiscal year 2026. That is unchanged from the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What are GROOVE BOTANICALS INC's total assets?

GROOVE BOTANICALS INC (GRVE) had $4K in total assets as of fiscal year 2026, including both current and long-term assets.

How many shares does GROOVE BOTANICALS INC have outstanding?

GROOVE BOTANICALS INC (GRVE) had 60M shares outstanding as of fiscal year 2026.

GROOVE BOTANICALS INC (GRVE) had a current ratio of 0.00 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

GROOVE BOTANICALS INC (GRVE) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $253K as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

GROOVE BOTANICALS INC (GRVE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $253K as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

GROOVE BOTANICALS INC (GRVE) has negative shareholder equity of -$1.5M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top